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Breast cancer survivors compose the largest group of cancer survivors in the United States. As heterogeneity exists within stages and between races in breast cancer survival, it is important to develop a better understanding of prognostic factors. Tumor estrogen and progesterone receptors are one of the more important prognostic factors in breast cancer patients. However, currently in clinical practice hormone receptor status is treated as either being present or absent and is treated similarly in all groups. The dichotomization of hormone status may lead to loss of valuable information and hormone receptor status may not have the same effect in African Americans and Whites. This historical cohort study evaluates quantitative differences in tumor hormone receptors in African Americans and Whites and determines whether survival effects differ between the two groups. This study also assesses whether a dose-response relationship, linear or nonlinear, exists between hormone receptors and survival. Findings of this study may lead to better prediction of survival and to identification of subsets of patients at higher risk that may have gone unrecognized by the application of a single cutpoint. Our preliminary findings indicate that African American breast cancer patients have more estrogen receptor negativity and a worse survival.
INTRODUCTION
Breast cancer survivors compose the largest group of cancer survivors in the United States today. As considerable heterogeneity exists within stages and between racial groups in breast cancer survival it is important to develop a better understanding of prognostic factors.
Estrogen and progesterone receptors in breast tumor tissue are regarded to be one of the more important prognostic factors in breast cancer patients. However, currently in clinical practice hormone receptor status is treated as either being present or absent and is treated similarly in all race/ethnic groups. The dichotomization of hormone status may lead to loss of valuable information and hormone receptor status may not have the same effect in African Americans and
Whites. This historical cohort study evaluates quantitative differences in estrogen and progesterone receptors in the breast tumors of African Americans and Whites and determines whether survival effects differ between the two groups. This study will also assess whether a dose-response relationship, linear or nonlinear, exists between quantitatively assessed hormone receptors and survival, as opposed to the currently popular dichotomized assessment of receptor status. Findings of this study may lead to better prediction of survival and to identification of subsets of patients needing particular clinical attention that may have gone unrecognized by applying one cutpoint to all patients.
BODY
Year one of this three-year study has been completed and the items in the Statement of Work that should have been undertaken and/or completed are summarized in Table 1 . As these databases are completed and cleaned up they will be merged. One issue that we are addressing is conflicting survival follow-up data. The HFHS Tumor Registry is usually current to up to within 6 months, whereas the SEER Tumor Registry is usually about 1 year behind in updating its files. Thus, one would expect the HFHS Tumor Registry to be preferred, however, the SEER Tumor Registry and the Michigan Death Registry data may capture survival c events lost to follow-up in the HFHS, and the latter will provide specific causes of death data.
Each conflicting survival case will be assessed individually. 
Preliminary Study Findings
Although the study is still in the early stages, an impression of the study population and data is offered. It must be emphasized that the data presented are preliminary and are likely to change -datasets are not complete and data has not been "cleaned".
The non-finalized dataset includes 1161 patients of whom 824 (71%) are whites and 337 (29%) are Black. The mean patient age is 60.1 years (SD 14.2) and the minimum, median and maximum ages are 24, 61, 94 years, respectively. The median follow-up of the breast cancer cohort is 11.4 years (95% CI 10.6-12.5). The median survival for African Americans was 10.6
(95% CI 9.1-12.2) years versus 11.6 (95% CI 10.6-13.3) years for Whites. A Kaplan-Meier survival plot describing the survival experience for these two groups is presented in Figure 1 . 
CONCLUSIONS
It is too early into the study to draw any substantive or methodologic conclusions.
However, the study is progression on schedule and within budget, and expects to present a more exciting report next year. Date Documented Duration L R Unk Q Q □ 01=Lump or mass Q □ □ 02=Pain Specify: 
COMORBIDITIES
Please record all of the comorbidities that the records indicate that the patient has had that are reported in the patients records from 3 years prior to diagnosis to 6 months following diagnosis or up until the first treatment, which ever comes first. The comorbidity did not have to have started during this period, it just needed to be documented in the medical records during this time period. As a default all conditions are coded 0, indicating not present. Column A provides a location to mark broader categories of comorbidity and Column B provides a site to mark more specific categories of comorbidities. Please provide as detailed information as possible, identifying (circling) comorbidities in both Columns A and B where possible.
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